Dr. Clay Siegall, is a co-founder of Seattle Genetics, which was stated in 1998. He is currently the President, Chief Executive Officer and Chairman of the Board of the company. Dr. Siegall, earned his B. S Degree in Zoology from the University of Maryland. He then received a Ph.D. in Genetics from George Washington University.
He has authored over 70 published articles and has 15 patents. From 1988 to 1991, Dr. Siegall worked with the National Cancer Institute, and National Institutes of Health. From 1991 to 1997 he was with Bristol=Myers Squibb Pharmaceutical Research Institute. He has received several different awards for his work, including the 2013 University of Maryland Alumnus of the Year award for Computer, Math and Natural Sciences. He also received the 2012 Pacific Northwest Ernst & Young Entrepreneur of the Year award. Clay serves on the Boards of Ultragenyx Pharmaceuticals Alder BioPharmaceuticals and the Washington Roundtable.
Seattle Genetics is built on the foundation of scientific innovation, intense research and drug development. Clay Siegall has helped the company reach a leadership position in developing antibody-drug conjugates. They have also received a 2011 FDA approval for ASCETRIS®. The company is in a collaboration with Takeda Pharmaceutical Company. Currently ADCETRIS is a global drug that is approved in more than 65 countries. Seattle Genetics is working on a number of proprietary ADCs for the treatment of various types of cancer.
With Dr. Siegall’s guidance, Seattle Genetics has become involved in multiple licenses for its ADC technology. It currently works with Genentech (Roche), AbbVie, Pfizer and GlaxoSmith Kline. The company has generated more thab $350 million in revenue to date. Seattle Genetics has secured more than $1.2 billion of funding over the years since its inception.